Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites

Chemico-Biological Interactions

Volumn 171, Issue 1, 2008, Pages 96-107

  Damsten, Micaela C ^a   van Vugt Lussenburg, Barbara M A ^a   Zeldenthuis, Tineke ^a   de Vlieger, Jon S B ^b   Commandeur, Jan N M ^a   Vermeulen, Nico P E ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Adverse drug reactions; Biocatalysis; Biotechnology; Directed evolution; Drug metabolism; Reactive metabolites

Indexed keywords

CLOZAPINE; CYTOCHROME P450 BM3; DICLOFENAC; DRUG METABOLITE; GLUTATHIONE; PARACETAMOL;

ANIMAL TISSUE; ARTICLE; BIOCATALYST; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; METABOLITE; NONHUMAN; RAT;

ACETAMINOPHEN; AMINO ACID SUBSTITUTION; ANIMALS; BACTERIAL PROTEINS; BIOTRANSFORMATION; CATALYSIS; CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; GLUTATHIONE; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; MUTATION; PHARMACEUTICAL PREPARATIONS; RATS; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

RATTUS;

EID: 36549051541     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.09.007     Document Type: Article

References (32)

1. Evans W.E., and Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (1999) 487-491
2. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270 (1994) 414-423
3. Baillie T.A. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19 (2006) 889-893
4. Caldwell G.W., and Yan Z. Screening for reactive intermediates and toxicity assessment in drug discovery. Curr. Opin. Drug Discov. Dev. 9 (2006) 47-60
5. Yan Z., and Caldwell G.W. Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal. Chem. 76 (2004) 6835-6847
6. Baillie T.A., and Davis M.R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22 (1993) 319-325
7. Masubuchi Y., Ose A., and Horie T. Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab. Dispos. 29 (2001) 1190-1195
8. Munro A.W., Leys D.G., Mclean K.J., Marshall K.R., Ost T.W., Daff S., Miles C.S., Chapman S.K., Lysek D.A., Moser C.C., Page C.C., and Dutton P.L. P450 BM3: the very model of a modern flavocytochrome. Trends Biochem. Sci. 27 (2002) 250-257
9. Van Vugt-Lussenburg B.M., Damsten M.C., Maasdijk D.M., Vermeulen N.P.E., and Commandeur J.N.M. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. Biochem. Biophys. Res. Commun. 346 (2006) 810-818
10. Van Vugt-Lussenburg B.M., Stjernschantz E., Lastdrager J., Oostenbrink C., Vermeulen N.P.E., and Commandeur J.N.M. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J. Med. Chem. 50 (2007) 455-461
11. Banks A.T., Zimmerman H.J., Ishak K.G., and Harter J.G. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22 (1995) 820-827
12. Bjornsson E., Jerlstad P., Bergqvist A., and Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand. J. Gastroenterol. 40 (2005) 1095-1101
13. Idanpaan-Heikkila J., Alhava E., Olkinuora M., and Palva I.P. Agranulocytosis during treatment with chlozapine. Eur. J. Clin. Pharmacol. 11 (1977) 193-198
14. Maggs J.L., Williams D., Pirmohamed M., and Park B.K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 275 (1995) 1463-1475
15. Pirmohamed M., Williams D., Madden S., Templeton E., and Park B.K. Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272 (1995) 984-990
16. Yan Z., Li J., Huebert N., Caldwell G.W., Du Y., and Zhong H. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab. Dispos. 33 (2005) 706-713
17. Patten C.J., Thomas P.E., Guy R.L., Lee M., Gonzalez F.J., Guengerich F.P., and Yang C.S. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. 6 (1993) 511-518
18. Bessems J.G., and Vermeulen N.P.E. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31 (2001) 55-138
19. Steffen H.S., Maurer C., Schmid R.D., and Urlacher V. Immobilisation of P450 BM-3 and an NADP + cofactor recycling system: towards a technical application of heme-containing monooxygenases in fine chemical synthesis. Adv. Synth. Catal. 345 (2003) 802-810
20. Kranendonk M., Carreira F., Theisen P., Laires A., Fisher C.W., Rueff J., Estabrook R.W., and Vermeulen N.P.E. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. Mutat. Res. 441 (1999) 73-83
21. Sandhu P., Baba T., and Guengerich F.P. Expression of modified cytochrome P450 2C10 (2C9) Escherichia coli, purification, and reconstitution of catalytic activity. Arch. Biochem. Biophys. 306 (1993) 443-450
22. Tartof K.D., and Hobbs C.A. New cloning vectors and techniques for easy and rapid restriction mapping. Gene 67 (1988) 169-182
23. Bessems J.G., Te Koppele J.M., Van Dijk P.A., Van Stee L.L., Commandeur J.N.M., and Vermeulen N.P.E. Rat liver microsomal cytochrome P450-dependent oxidation of 3,5-disubstituted analogues of paracetamol. Xenobiotica 26 (1996) 647-666
24. Lee C.A., Manyike P.T., Thummel K.E., Nelson S.D., and Slattery J.T. Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes. Drug Metab. Dispos. 25 (1997) 1150-1156
25. Tugnait M., Hawes E.M., Mckay G., Eichelbaum M., and Midha K.K. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem. Biol. Interact. 118 (1999) 171-189
26. Schaber G., Wiatr G., Wachsmuth H., Dachtler M., Albert K., Gaertner I., and Breyer-Pfaff U. Isolation and identification of clozapine metabolites in patient urine. Drug Metab. Dispos. 29 (2001) 923-931
27. Leemann T., Transon C., and Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci. 52 (1993) 29-34
28. Shen S., Marchick M.R., Davis M.R., Doss G.A., and Pohl L.R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. 12 (1999) 214-222
29. Tang W., Stearns R.A., Wang R.W., Chiu S.H., and Baillie T.A. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 12 (1999) 192-199
30. Tang W., Stearns R.A., Bandiera S.M., Zhang Y., Raab C., Braun M.P., Dean D.C., Pang J., Leung K.H., Doss G.A., Strauss J.R., Kwei G.Y., Rushmore T.H., Chiu S.H., and Baillie T.A. Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab. Dispos. 27 (1999) 365-372
31. Yu L.J., Chen Y., Deninno M.P., O'Connell T.N., and Hop C.E. Identification of a novel glutathione adduct of diclofenac, 4'-hydroxy-2'-glutathion-deschloro-diclofenac, upon incubation with human liver microsomes. Drug Metab. Dispos. 33 (2005) 484-488
32. Madsen K.G., Olsen J., Skonberg C., Hansen S.H., and Jurva U. Development and evaluation of an electrochemical method for studying reactive phase-I metabolites: correlation to in vitro drug metabolism. Chem. Res. Toxicol. 20 (2007) 821-831